Beam Therapeutics (BEAM) insider Amy Simon plans sale of 16,677 common shares

Rhea-AI Filing Summary

Beam Therapeutics Inc. beneficial owner Amy Simon submitted a notice of intent to sell common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The notice covers up to 16,677 shares of common stock, with an aggregate market value of $429,294.33, to be sold on or after July 27, 2026 on the NASDAQ market.

The shares to be sold include 15,800 restricted stock shares dated March 31, 2026 and 877 restricted stock shares dated June 30, 2026. In addition, during the prior three months, Amy Simon sold 373 common shares on July 1, 2026 for $12,953.02.

Key Figures

Shares planned for sale: 16,677 shares Aggregate market value: $429,294.33 Restricted stock dated 03/31/2026: 15,800 shares +3 more

6 metrics

Shares planned for sale 16,677 shares Common stock to be sold on or after July 27, 2026 on NASDAQ

Aggregate market value $429,294.33 Market value of 16,677 Beam Therapeutics common shares covered by the notice

Restricted stock dated 03/31/2026 15,800 shares Restricted common stock of the issuer included in the planned sale

Restricted stock dated 06/30/2026 877 shares Restricted common stock of the issuer included in the planned sale

Recent shares sold 373 shares Common shares sold on July 1, 2026 during the past three months

Proceeds from recent sale $12,953.02 Total received for 373 common shares sold on July 1, 2026

Key Terms

Form 144, Restricted Stock, Executive Financial Services

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock financial

"Common | 03/31/2026 | Restricted Stock | ISSUER"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:05 PM Accepted by SEC EDGAR 07/27/2026 - 04:04 PM Learn about SEC filing dates

FAQ

What does Beam Therapeutics (BEAM) insider Amy Simon plan to sell under this Form 144?

Amy Simon has filed a notice to sell up to 16,677 shares of Beam Therapeutics common stock. The planned sale has an aggregate market value of $429,294.33 and is expected to occur on or after July 27, 2026 on NASDAQ.

What types of Beam Therapeutics (BEAM) shares are covered by Amy Simon’s planned sale?

The planned sale covers restricted stock in Beam Therapeutics. It includes 15,800 restricted shares dated March 31, 2026 and 877 restricted shares dated June 30, 2026, all designated as common stock of the issuer.

What is the aggregate market value of Beam Therapeutics (BEAM) shares in Amy Simon’s planned sale?

The aggregate market value of the common shares covered by Amy Simon’s notice is $429,294.33. This value relates to the planned sale of up to 16,677 Beam Therapeutics common shares on or after July 27, 2026.

When can the Beam Therapeutics (BEAM) shares be sold under Amy Simon’s Form 144?

The notice specifies that the 16,677 Beam Therapeutics common shares may be sold on or after July 27, 2026. Sales are to be executed on the NASDAQ market through Morgan Stanley Smith Barney LLC Executive Financial Services.

What Beam Therapeutics (BEAM) stock transactions has Amy Simon made in the last 3 months?

Within the past three months, Amy Simon sold 373 Beam Therapeutics common shares on July 1, 2026, receiving total proceeds of $12,953.02. This prior transaction is reported alongside the new planned sale notice.

Which broker is handling Amy Simon’s planned Beam Therapeutics (BEAM) share sale?

The notice lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker. The firm, based at 1 New York Plaza, is designated to handle the planned NASDAQ sale of Beam Therapeutics common stock.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	16677	429294.33	102879214	07/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/31/2026	Restricted Stock	ISSUER			15800	03/31/2026	Not Applicable
Common	06/30/2026	Restricted Stock	ISSUER			877	06/30/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMY SIMON 238 Main Street Cambridge MA 02142	Common	07/01/2026	373	12953.02

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)